Reinhard Kandera
Directeur Financier/CFO chez HOOKIPA PHARMA INC.
Fortune : 34 732 $ au 30/04/2024
Postes actifs de Reinhard Kandera
Sociétés | Poste | Début | Fin |
---|---|---|---|
IOMAI CORPORATION | Directeur/Membre du Conseil | - | - |
Secrétaire Général | - | - | |
Directeur Financier/CFO | - | - | |
HOOKIPA PHARMA INC. | Directeur/Membre du Conseil | 01/06/2018 | - |
Directeur Financier/CFO | 01/04/2017 | - | |
Elatos GmbH | Corporate Officer/Principal | 01/12/2013 | - |
Vaccines Holdings Sweden AB
Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Reinhard Kandera
Anciens postes connus de Reinhard Kandera
Sociétés | Poste | Début | Fin |
---|---|---|---|
VALNEVA | Directeur Financier/CFO | 10/05/2013 | - |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Directeur Financier/CFO | 01/11/2009 | 28/05/2013 |
Investor Relations Contact | 18/05/2011 | 28/05/2013 | |
Public Communications Contact | 23/08/2011 | 28/05/2013 | |
Valneva Austria GmbH
Valneva Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013. | Corporate Officer/Principal | 01/08/2013 | - |
Valneva Scotland Ltd.
Valneva Scotland Ltd. BiotechnologyHealth Technology Part of Valneva SE, Valneva Scotland Ltd. is a British vaccine company that specializes in the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is based in Livingston, UK. The company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and chikungunya. Valneva's portfolio also includes two commercial vaccines for travelers. | Directeur/Membre du Conseil | 30/04/2012 | - |
Secrétaire Général | 04/08/2009 | - |
Formation de Reinhard Kandera
Vienna University of Economics & Business | Doctorate Degree |
University of Vienna | Graduate Degree |
Statistiques
Internationale
Autriche | 6 |
Etats-Unis | 3 |
France | 2 |
Opérationnelle
Director of Finance/CFO | 4 |
Director/Board Member | 4 |
Corporate Secretary | 2 |
Sectorielle
Health Technology | 7 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
VALNEVA | Health Technology |
HOOKIPA PHARMA INC. | Health Technology |
Entreprise privées | 6 |
---|---|
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria. | Health Technology |
Intercell USA, Inc.
Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
Valneva Scotland Ltd.
Valneva Scotland Ltd. BiotechnologyHealth Technology Part of Valneva SE, Valneva Scotland Ltd. is a British vaccine company that specializes in the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is based in Livingston, UK. The company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and chikungunya. Valneva's portfolio also includes two commercial vaccines for travelers. | Health Technology |
Valneva Austria GmbH
Valneva Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013. | Commercial Services |
Elatos GmbH | |
Vaccines Holdings Sweden AB
Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | Health Technology |
- Bourse
- Insiders
- Reinhard Kandera
- Expérience